Literature DB >> 20578941

Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer.

Rong-Rong Jing1, Ming Cui, Bao-Lan Sun, Juan Yu, Hui-Min Wang.   

Abstract

The receptor for advanced glycation end products (RAGE) interacts with several ligands and is involved in various human diseases. Several splicing forms of the RAGE gene have been characterized, and two general mechanisms are usually responsible for the generation of soluble receptors. However, variants distribution and respective roles in different tumors are not clear. We analyzed RAGE and hRAGEsec mRNA expression in esophageal and lung cancer by RT-polymerase chain reaction. The Agilent clipper 1000 Bioanalyzer using lab-on-a-chip technology was applied to size and quantify the polymerase chain reaction products. Western blotting was performed to measure total soluble RAGE protein levels. The results showed that RAGE and its splice variants increased in esophageal cancers and decreased in lung cancers. We conclude that RAGE presents as a major isoform; soluble RAGE may also play certain roles in esophageal cancer and lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578941     DOI: 10.1089/gtmb.2009.0064

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  10 in total

1.  Relationship of advanced glycation end products and their receptor to pelvic organ prolapse.

Authors:  Yisong Chen; Jian Huang; Changdong Hu; Keqin Hua
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma.

Authors:  Jing Gao; Zhengzhi Zou; Jing Gao; Haifang Zhang; Zhicai Lin; Yaya Zhang; Xianyang Luo; Changhua Liu; Jingdun Xie; Chengfu Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  Int Immunol       Date:  2011-10-24       Impact factor: 4.823

4.  Concurrent alterations of RAGE, RECK, and MMP9 protein expression are relevant to Epstein-Barr virus infection, metastasis, and survival in nasopharyngeal carcinoma.

Authors:  Dong-Ni Zhou; Yan-Fei Deng; Rong-Hua Li; Ping Yin; Chun-Sheng Ye
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  Emulsion PCR: a high efficient way of PCR amplification of random DNA libraries in aptamer selection.

Authors:  Keke Shao; Weifeng Ding; Feng Wang; Haiquan Li; Da Ma; Huimin Wang
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

6.  Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats.

Authors:  Fujiang Wang; Qiansong He; Jinxin Wang; Qing Yuan; Hong Guo; Lijuan Chai; Shaoxia Wang; Limin Hu; Yue Zhang
Journal:  BMC Complement Altern Med       Date:  2017-05-10       Impact factor: 3.659

7.  SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma.

Authors:  Weiguo Zhang; Junli Fan; Qiang Chen; Caipeng Lei; Bin Qiao; Qin Liu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

8.  RAGE is a potential biomarker implicated in immune infiltrates and cellular senescence in lung adenocarcinoma.

Authors:  Zhihui Lin; Biyun Yu; Li Yuan; Jinjing Tu; Chuan Shao; Yaodong Tang
Journal:  J Clin Lab Anal       Date:  2022-03-31       Impact factor: 3.124

9.  Contributory role of five common polymorphisms of RAGE and APE1 genes in lung cancer among Han Chinese.

Authors:  Hongming Pan; Wenquan Niu; Lan He; Bin Wang; Jun Cao; Feng Zhao; Ying Liu; Shen Li; Huijian Wu
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

10.  Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells.

Authors:  Qiong Wang; Wenwen Zhu; Geqiong Xiao; Mengyu Ding; Jian Chang; Hui Liao
Journal:  Mol Med Rep       Date:  2020-05-22       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.